-
1
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
2
-
-
0036984640
-
Role of angiogenesis in tumor growth and metastasis
-
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
-
(2002)
Semin Oncol
, vol.29
, pp. 15-18
-
-
Folkman, J.1
-
3
-
-
13444278498
-
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
-
Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
-
(2005)
Cancer Res
, vol.65
, pp. 671-680
-
-
Gerber, H.P.1
Ferrara, N.2
-
4
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
DOI 10.1200/JCO.2006.09.6305
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, SchwartzMA, Benson AB 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544 (Pubitemid 46733080)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson III, A.B.8
-
5
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer. N Engl J Med 350:2335-2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
6
-
-
20644432867
-
Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
-
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508
-
(2005)
J Clin Oncol
, vol.23
, pp. 3502-3508
-
-
Hurwitz, H.I.1
Fehrenbacher, L.2
Hainsworth, J.D.3
Heim, W.4
Berlin, J.5
Holmgren, E.6
Hambleton, J.7
Novotny, W.F.8
Kabbinavar, F.9
-
7
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
Griffing, S.7
Bergsland, E.8
-
8
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
Scheithauer, W.4
Figer, A.5
Wong, R.6
Koski, S.7
Lichinitser, M.8
Yang, T.S.9
Rivera, F.10
Couture, F.11
Sirzén, F.12
Cassidy, J.13
-
9
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
-
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705
-
(2005)
J Clin Oncol
, vol.23
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
Patel, T.4
Hamm, J.T.5
Hecht, J.R.6
Mass, R.7
Perrou, B.8
Nelson, B.9
Novotny, W.F.10
-
10
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
DOI 10.1056/NEJMoa061884
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
11
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
Shenkier, T.7
Cella, D.8
Davidson, N.E.9
-
12
-
-
54249120945
-
Randomized, double-blind,placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
-
Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG (2008) Randomized, double-blind,placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 26:LBA1011
-
(2008)
Proc Am Soc Clin Oncol
, vol.26
-
-
Miles, D.1
Chan, A.2
Romieu, G.3
Dirix, L.Y.4
Cortes, J.5
Pivot, X.6
Tomczak, P.7
Taran, T.8
Harbeck, N.9
Steger, G.G.10
-
13
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799
-
(2005)
J Clin Oncol
, vol.23
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
Cobleigh, M.A.4
Marcom, P.K.5
Fehrenbacher, L.6
Dickler, M.7
Overmoyer, B.A.8
Reimann, J.D.9
Sing, A.P.10
Langmuir, V.11
Rugo, H.S.12
-
14
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
Stadler, W.M.4
Vaena, D.A.5
Ou, S.S.6
Archer, L.7
Atkins, J.N.8
Picus, J.9
Czaykowski, P.10
Dutcher, J.11
Small, E.J.12
-
15
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
DOI 10.1016/S0140-6736(07)61904-7, PII S0140673607619047
-
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a odifyzed, double-blind phase III trial. Lancet 370:2103-2111 (Pubitemid 350296300)
-
(2007)
Lancet
, vol.370
, Issue.9605
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.-O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
16
-
-
84885707194
-
-
Available at; Accessed 27 Oct 2008
-
Genentech. Bevacizumab prescribing information. Available at; http://www.Gene.com/gene/products/information/oncology/avastin/. Accessed 27 Oct 2008
-
Bevacizumab Prescribing Information
-
-
-
17
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
-
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M.1
Von Pawel, J.2
Zatloukal, P.3
Ramlau, R.4
Gorbounova, V.5
Hirsh, V.6
Leighl, N.7
Mezger, J.8
Archer, V.9
Moore, N.10
Manegold, C.11
-
18
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
DOI 10.1200/JCO.2004.11.022
-
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191 (Pubitemid 41095154)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.11
, pp. 2184-2191
-
-
Johnson, D.H.1
Fehrenbacher, L.2
Novotny, W.F.3
Herbst, R.S.4
Nemunaitis, J.J.5
Jablons, D.M.6
Langer, C.J.7
DeVore III, R.F.8
Gaudreault, J.9
Damico, L.A.10
Holmgren, E.11
Kabbinavar, F.12
-
19
-
-
36048982143
-
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
-
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25:474-4750
-
(2007)
J Clin Oncol
, vol.25
, pp. 474-4750
-
-
Herbst, R.S.1
O'Neill, V.J.2
Fehrenbacher, L.3
Belani, C.P.4
Bonomi, P.D.5
Hart, L.6
Melnyk, O.7
Ramies, D.8
Lin, M.9
Sandler, A.10
-
20
-
-
54249108586
-
Initial safety report of NSABP C-08, a randomized phase III study of odify ed 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer
-
Abstr 4006
-
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Wolmark N (2008) Initial safety report of NSABP C-08, a randomized phase III study of odify ed 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc Am Soc Clin Oncol 26 [15 Suppl]: Abstr 4006
-
(2008)
Proc Am Soc Clin Oncol
, vol.26
, Issue.15 SUPPL.
-
-
Allegra, C.J.1
Yothers, G.2
O'Connell, M.J.3
Sharif, S.4
Wolmark, N.5
-
21
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237
-
(2009)
J Clin Oncol
, vol.27
, pp. 2231-2237
-
-
Van Cutsem, E.1
Vervenne, W.L.2
Bennouna, J.3
Humblet, Y.4
Gill, S.5
Van Laethem, J.L.6
Verslype, C.7
Scheithauer, W.8
Shang, A.9
Cosaert, J.10
Moore, M.J.11
-
22
-
-
35548941394
-
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)
-
Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin Oncol 25:4508
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, pp. 4508
-
-
Kindler, H.L.1
Niedzwiecki, D.2
Hollis, D.3
Oraefo, E.4
Schrag, D.5
Hurwitz, H.6
McLeod, H.L.7
Mulcahy, M.F.8
Schilsky, R.L.9
Goldberg, R.M.10
-
23
-
-
40749158416
-
Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
-
Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, Stadler WM, Vokes E (2007) Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 25:7526
-
(2007)
J Clin Oncol
, vol.25
, pp. 7526
-
-
Karrison, T.1
Kindler, H.L.2
Gandara, D.R.3
Lu, C.4
Guterz, T.L.5
Nichols, K.6
Chen, H.7
Stadler, W.M.8
Vokes, E.9
-
24
-
-
79959725695
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 27:2231-2237
-
(2003)
N Engl J Med
, vol.27
, pp. 2231-2237
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
Hwu, P.4
Schwartzentruber, D.J.5
Topalian, S.L.6
Steinberg, S.M.7
Chen, H.X.8
Rosenberg, S.A.9
-
25
-
-
77958495206
-
AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
-
Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA (2010) AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28: LBA4007
-
(2010)
J Clin Oncol
, vol.28
-
-
Kang, Y.1
Ohtsu, A.2
Van Cutsem, E.3
Rha, S.Y.4
Sawaki, A.5
Park, S.6
Lim, H.7
Wu, J.8
Langer, B.9
Shah, M.A.10
-
26
-
-
66149133167
-
International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
-
Price TJ, Gebski V, van Hazel GA, Robinson BA, Broad A, Ganju V, Cunningham D, Wilson K, Tunney V, Tebbutt NC (2008) International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. J Clin Oncol 26:4029
-
(2008)
J Clin Oncol
, vol.26
, pp. 4029
-
-
Price, T.J.1
Gebski, V.2
Van Hazel, G.A.3
Robinson, B.A.4
Broad, A.5
Ganju, V.6
Cunningham, D.7
Wilson, K.8
Tunney, V.9
Tebbutt, N.C.10
-
27
-
-
18744380623
-
Bevacizumab does not pressure bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation
-
Hambleton J, Novotny WF, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E (2004) Bevacizumab does not pressure bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol 22:3528
-
(2004)
J Clin Oncol
, vol.22
, pp. 3528
-
-
Hambleton, J.1
Novotny, W.F.2
Hurwitz, H.3
Fehrenbacher, L.4
Cartwright, T.5
Hainsworth, J.6
Heim, W.7
Berlin, J.8
Kabbinavar, F.9
Holmgren, E.10
-
28
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
-
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12
-
(1996)
Control Clin Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
Jenkinson, C.4
Reynolds, D.J.5
Gavaghan, D.J.6
McQuay, H.J.7
-
29
-
-
0029983193
-
The importance of quality of primary studies in producing unbiased systematic reviews
-
DOI 10.1001/archinte.156.6.661
-
Khan KS, Daya S, Jadad A (1996) The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 156:661-666 (Pubitemid 26095017)
-
(1996)
Archives of Internal Medicine
, vol.156
, Issue.6
, pp. 661-666
-
-
Khan, K.S.1
Daya, S.2
Jadad, A.R.3
-
31
-
-
0022992740
-
Meta-analysis in clinical trials
-
DOI 10.1016/0197-2456(86)90046-2
-
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188 (Pubitemid 17189972)
-
(1986)
Controlled Clinical Trials
, vol.7
, Issue.3
, pp. 177-188
-
-
DerSimonian, R.1
Laird, N.2
-
32
-
-
70349393610
-
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials
-
Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974
-
(2009)
Lancet Oncol
, vol.10
, pp. 967-974
-
-
Je, Y.1
Schutz, F.A.2
Choueiri, T.K.3
-
33
-
-
34250365240
-
Mechanisms of adverse effects of anti-VEGF therapy for cancer
-
DOI 10.1038/sj.bjc.6603813, PII 6603813
-
Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795 (Pubitemid 46912024)
-
(2007)
British Journal of Cancer
, vol.96
, Issue.12
, pp. 1788-1795
-
-
Kamba, T.1
McDonald, D.M.2
-
34
-
-
0142121282
-
Bevacizumab, bleeding, thrombosis, and warfarin
-
Kilickap S, Abali H, Celik I (2003) Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21:3542-3543
-
(2003)
J Clin Oncol
, vol.21
, pp. 3542-3543
-
-
Kilickap, S.1
Abali, H.2
Celik, I.3
-
35
-
-
34249748593
-
A study of clinical and radiographic risk factors associated with early onset severe pulmonary hemorrhage in bevacizumab (Avastin) treated patients with advanced non-small cell lung cancer
-
SandlerAB JDH, Brahmer J et al (2006) A study of clinical and radiographic risk factors associated with early onset severe pulmonary hemorrhage in bevacizumab (Avastin) treated patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 24:7068
-
(2006)
Proc Am Soc Clin Oncol
, vol.24
, pp. 7068
-
-
Sandler, A.B.J.D.H.1
Brahmer, J.2
-
36
-
-
63049122188
-
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall- cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab
-
Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall- cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27:1405-1412
-
(2009)
J Clin Oncol
, vol.27
, pp. 1405-1412
-
-
Sandler, A.B.1
Schiller, J.H.2
Gray, R.3
Dimery, I.4
Brahmer, J.5
Samant, M.6
Wang, L.I.7
Johnson, D.H.8
-
37
-
-
48649098245
-
Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
-
Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R (2008) von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180:860-866
-
(2008)
J Urol
, vol.180
, pp. 860-866
-
-
Choueiri, T.K.1
Vaziri, S.A.2
Jaeger, E.3
Elson, P.4
Wood, L.5
Bhalla, I.P.6
Small, E.J.7
Weinberg, V.8
Sein, N.9
Simko, J.10
Golshayan, A.R.11
Sercia, L.12
Zhou, M.13
Waldman, F.M.14
Rini, B.I.15
Bukowski, R.M.16
Ganapathi, R.17
-
38
-
-
58749110442
-
Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRITE observational cohort study (OCS)
-
Flynn PJ, Sugrue MM, Feng S, Purdie DM, Grothey A, Sargent DJ, Berlin JD, Kabbinavar FF, Dong W, Kozloff MF (2008) Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRITE observational cohort study (OCS). J Clin Oncol 26:4104
-
(2008)
J Clin Oncol
, vol.26
, pp. 4104
-
-
Flynn, P.J.1
Sugrue, M.M.2
Feng, S.3
Purdie, D.M.4
Grothey, A.5
Sargent, D.J.6
Berlin, J.D.7
Kabbinavar, F.F.8
Dong, W.9
Kozloff, M.F.10
-
39
-
-
78049382933
-
Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta-analysis
-
Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27-38
-
(2010)
Oncology
, vol.79
, pp. 27-38
-
-
Hapani, S.1
Sher, A.2
Chu, D.3
Wu, S.4
-
40
-
-
0032501730
-
Summing up evidence: One answer is not always enough
-
DOI 10.1016/S0140-6736(97)08468-7
-
Lau J, Ioannidis JPA, Schmid CH (1997) summing up the evidence: one answer is not always enough. Lancet 351:123-127 (Pubitemid 28026648)
-
(1998)
Lancet
, vol.351
, Issue.9096
, pp. 123-127
-
-
Lau, J.1
Ioannidis, J.P.A.2
Schmid, C.H.3
-
41
-
-
0028152471
-
Why sources of heterogeneity in metaanalysis should be investigated
-
Thompson SG (1994) Why sources of heterogeneity in metaanalysis should be investigated. Br Med J 309:1351-1355
-
(1994)
Br Med J
, vol.309
, pp. 1351-1355
-
-
Thompson, S.G.1
|